Metabolic modulator is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Etizolam, a thienodiazepine derivative, is absorbed fairly rapidly, with peak plasma levels achieved between 30 minutes and 2 hours. It has a mean elimination half-life of about 3.4 hours. Etizolam possesses potent hypnotic properties, and is comparable with other short-acting benzodiazepines. Etizolam acts as a positive allosteric modulator of the GABAA receptor by agonizing the receptor's benzodiazepine site. According to the Italian prescribing information sheet, etizolam belongs to a new class of diazepines, thienotriazolodiazepines. This new class is easily oxidized, rapidly metabolized, and has a lower risk of accumulation, even after prolonged treatment. Etizolam has an anxiolytic action about 6–8 times greater than that of diazepam. Etizolam produces, especially at higher dosages, a reduction in time taken to fall asleep, an increase in total sleep time, and a reduction in the number of awakenings. During tests, there were no substantial changes in deep sleep; however, it may reduce REM sleep. In EEG tests of healthy volunteers, etizolam showed some similar characteristics to tricyclic antidepressants. Etizolam's main metabolites in humans are alpha-hydroxyetizolam and 8-hydroxyetizolam. alpha-Hydroxyetizolam is pharmacologically active and has a half-life of approximately 8.2 hours.
== Examples and nomenclature == Carboxylic acids are commonly identified by their trivial names. They often have the suffix -ic acid. IUPAC-recommended names also exist; in this system, carboxylic acids have an -oic acid suffix. For example, butyric acid (CH3CH2CH2CO2H) is butanoic acid by IUPAC guidelines. For nomenclature of complex molecules containing a carboxylic acid, the carboxyl can be considered position one of the parent chain even if there are other substituents, such as 3-chloropropanoic acid. Alternately, it can be named as a "carboxy" or "carboxylic acid" substituent on another parent structure, such as 2-carboxyfuran. The carboxylate anion (R−COO− or R−CO−2) of a carboxylic acid is usually named with the suffix -ate, in keeping with the general pattern of -ic acid and -ate for a conjugate acid and its conjugate base, respectively. For example, the conjugate base of acetic acid is acetate. Carbonic acid, which occurs in bicarbonate buffer systems in nature, is not generally classed as one of the carboxylic acids, despite it having a moiety that looks like a COOH group.
The Kuwaiti oil fires were caused by the Iraqi military setting fire to 700 oil wells as part of a scorched earth policy while retreating from Kuwait in 1991 after conquering the country but being driven out by coalition forces. The fires started in January and February 1991, and the last one was extinguished by November. The resulting fires burned uncontrollably because of the dangers of sending in firefighting crews. Land mines had been placed in areas around the oil wells, and a military cleaning of the areas was necessary before the fires could be put out. Somewhere around 6 million barrels (950,000 m3) of oil were lost each day. Eventually, privately contracted crews extinguished the fires, at a total cost of US$1.5 billion to Kuwait. By that time, however, the fires had burned for approximately 10 months, causing widespread pollution.
=== Mechanically interlocked molecular architectures === Mechanically interlocked molecular architectures consist of molecules that are linked only as a consequence of their topology. Some non-covalent interactions may exist between the different components (often those that were used in the construction of the system), but covalent bonds do not. Supramolecular chemistry, and template-directed synthesis in particular, is key to the efficient synthesis of the compounds. Examples of mechanically interlocked molecular architectures include catenanes, rotaxanes, molecular knots, molecular Borromean rings, 2D [c2]daisy chain polymer and ravels.
=== Safety screening === DSC makes a reasonable initial safety screening tool. In this mode the sample will be housed in a non-reactive crucible (often gold or gold-plated steel), and which will be able to withstand pressure (typically up to 100 bar). The presence of an exothermic event can then be used to assess the stability of a substance to heat. However, due to a combination of relatively poor sensitivity, slower than normal scan rates (typically 2–3 °C/min, due to much heavier crucible) and unknown activation energy, it is necessary to deduct about 75–100 °C from the initial start of the observed exotherm to suggest a maximal temperature for the material. A much more accurate data set can be obtained from an adiabatic calorimeter, but such a test may take 2–3 days from ambient at a rate of a 3 °C increment per half-hour.
Sources: en.wikipedia.org
== Life and education == Christian Hackenberger grew up in Damme. He attended the Gymnasium Damme, where he obtained his Abitur in 1995. After completing his civil service, he studied chemistry at the Albert-Ludwigs-Universität in Freiburg (1996–1998) and the University of Wisconsin-Madison (M.S. with Samuel H. Gellman, 1998–1999), with support from the German Academic Scholarship Foundation. He pursued his doctoral studies at the RTWH Aachen (2000–2003), where he worked under Prof. Carsten Bolm as a Kekulé Fellow from the Fonds der Chemischen Industrie. During this time, he also worked as an editorial assistant in scientific journalism for the WDR broadcast "Quarks & Co". From 2003 to 2005 he was a DAAD Postdoctoral Fellow at the Massachusetts Institute of Technology under Prof. Barbara Imperiali. In 2005, Hackenberger founded his own research group at the Free University of Berlin in 2005 as an Emmy Noether Fellow. In 2011, he was appointed as W2 Professor of Bioorganic Chemistry at the Free University of Berlin as the first Plus 3 awardee from the Boehringer Ingelheim Foundation. In 2012, he became Leibniz-Humboldt Professor for Chemical Biology at the Leibniz Research Institute for Molecular Pharmacology and the Humboldt University of Berlin. In 2020, Hackenberger co-founded the Munich-based biotechnology company Tubulis, which specializes in developing antibody-drug conjugates. He has served as associate editor of the Royal Society of Chemistry's scientific journals Organic and Biomolecular Chemistry (2015–2023) and Chemical Science (since 2024).
=== Antiandrogens === Antiandrogens are a class of drug which bind and inhibit the androgen receptor, blocking the growth- and survival-promoting effects of testosterone on certain prostate cancers. Flutamide and bicalutamide are antiandrogens which are frequently used in the treatment of prostate cancer, either as long-term monotherapy, or in the initial few weeks of GnRH analog therapy. (See also Androgen deprivation therapy)
Patrice Motsepe, businessman Herman Mashaba, businessman, president of ActionSA Mogoeng Mogoeng, former chief justice of South Africa Mamokgethi Phakeng, former vice chancellor of the University of Cape Town Tshepo Motsepe, businesswoman and first lady of South Africa Baaitse Nkabinde, former judge at the South African high court Refiloe Phoolo, musician and businessman Thato Sikwane, disk jockey and music producer Connie Ferguson, actress, film producer and businesswoman Motsi Mabuse, dancer and judge on Strictly Come Dancing
RTS is caused by a mutation of the RECQL4 gene, located at chromosome 8q24.3. The disorder is inherited in an autosomal recessive manner. This means the defective gene responsible for the disorder is located on an autosome (chromosome 8 is an autosome), and two copies of the defective gene (one inherited from each parent) are required in order to be born with the disorder. The parents of an individual with an autosomal recessive disorder both carry one copy of the defective gene, but usually do not experience any signs or symptoms of the disorder.
Besides exercise-induced premature muscle fatigue, GSD-V individuals may also have comorbidities of mental fatigue, general fatigue, reduced motivation, sleep disturbances, anxiety, and depression. As skeletal muscle relies predominantly on glycogenolysis for the first few minutes as it transitions from rest to activity, as well as throughout high-intensity aerobic activity and all anaerobic activity, individuals with GSD-V experience during exercise: sinus tachycardia, tachypnea, muscle fatigue and pain, during the aforementioned activities and time frames. They may exhibit a "second wind" phenomenon, which is characterized by the individual's better tolerance for aerobic exercise such as walking and cycling after approximately 10 minutes. This is attributed to the combination of increased blood flow and the ability of the body to find alternative sources of energy, like fatty acids, proteins, and increased blood glucose uptake. AMP is primarily produced from the myokinase (adenylate kinase) reaction, which runs when the ATP reservoir is low. The myokinase reaction is one of three reactions in the phosphagen system (ATP-PCr), with the myokinase reaction occurring after phosphocreatine (creatine phosphate) has been depleted. In McArdle disease individuals, their muscle cells produce far more AMP than non-affected individuals as the reduced glycolytic flux from impaired glycogenolysis results in a chronically low ATP reservoir during exercise.
Sources: en.wikipedia.org
== Cost == In Canada, PET scan funding varies by province. In Ontario, as of October 2025, there is no charge to the patient for any PET scans funded as part of the PET Scans Ontario Program. The program funds routine PET services for indications where sufficient evidence exists that the scan benefits the patient and offers advantages over other imaging tests. In the United States, PET scan costs vary significantly by location, facility type, and insurance status. According to Medicare's 2026 payment data, a whole-body PET scan has a national average total cost of $872, with the patient paying approximately $174 after Medicare coverage. In the United Kingdom, the National Health Service provides PET-CT scans free at point of use for eligible patients. In Australia, Medicare subsidies are available for eligible PET services.
In 1990, the USDA's Food Safety and Inspection Service (FSIS) approved the use of the technology for manufacturing finely textured meat. At the time of its approval, the FSIS called the remaining product "meat", although one FSIS microbiologist dissented, arguing it contained both muscle and connective tissue. In 1994, in response to public health concerns over pathogenic E. coli in beef, the founder of BPI, Eldon Roth, began work on the "pH Enhancement System", which disinfects meat using injected anhydrous ammonia in gaseous form, rapid freezing to 28 °F (−2 °C), and mechanical stress. In 2001, the FSIS approved the gaseous disinfection system as an intermediate step before the roller press freezer, and approved the disinfected product for human consumption, as an additive. The FSIS agreed with BPI's suggestion that ammonia was a "processing agent" which did not need to be listed on labels as an ingredient. FSIS microbiologists Carl Custer and Gerald Zirnstein stated that they argued against the product's approval for human consumption, saying that it was not "meat" but actually "salvage", and that the USDA should seek independent verification of its safety, but they were overruled. In 2003, BPI commissioned a study of the effectiveness and safety of the disinfection process; the Iowa State University researchers found no safety concern in the product or in ground beef containing it. The term "pink slime", a reference to the product's "distinctive look", was coined in 2002 by Zirnstein in an internal FSIS e-mail.
=== Marketing === Diphenhydramine is sold under the brand name Benadryl by McNeil Consumer Healthcare in the US, UK, Canada, and South Africa. Trade names in other countries include Dimedrol, Daedalon, Nytol, and Vivinox. It is also available as a generic medication. Procter & Gamble markets an over-the-counter formulation of diphenhydramine as a sleep aid under the brand ZzzQuil. Prestige Brands markets an over-the-counter formulation of diphenhydramine as a sleep aid in the US under the name Sominex.
Guo Li Zhuang is a Chinese cuisine restaurant that specializes in penis dishes. The restaurant features table-side traditional Chinese medicine nutritionists that recommend dishes based on diners' ailments; penises offered include dog, goat, deer, bull, ox, yak, sheep, horse, donkey, and seal. The restaurant has expanded from America to China, with multiple locations in the Beijing area.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.